356 related articles for article (PubMed ID: 33925949)
21. Versatile CAR T-cells for cancer immunotherapy.
Chu F; Cao J; Neelalpu SS
Contemp Oncol (Pozn); 2018 Mar; 22(1A):73-80. PubMed ID: 29628798
[TBL] [Abstract][Full Text] [Related]
22. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
23. Counteracting CAR T cell dysfunction.
Poorebrahim M; Melief J; Pico de Coaña Y; L Wickström S; Cid-Arregui A; Kiessling R
Oncogene; 2021 Jan; 40(2):421-435. PubMed ID: 33168929
[TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572932
[TBL] [Abstract][Full Text] [Related]
25. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
26. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.
Kankeu Fonkoua LA; Sirpilla O; Sakemura R; Siegler EL; Kenderian SS
Mol Ther Oncolytics; 2022 Jun; 25():69-77. PubMed ID: 35434273
[TBL] [Abstract][Full Text] [Related]
27. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
Hawkins ER; D'Souza RR; Klampatsa A
Biologics; 2021; 15():95-105. PubMed ID: 33883875
[TBL] [Abstract][Full Text] [Related]
28. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions.
Montironi C; Muñoz-Pinedo C; Eldering E
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466674
[TBL] [Abstract][Full Text] [Related]
30. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
31. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
33. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
34. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
35. Modulating tumor physical microenvironment for fueling CAR-T cell therapy.
Luo Z; Yao X; Li M; Fang D; Fei Y; Cheng Z; Xu Y; Zhu B
Adv Drug Deliv Rev; 2022 Jun; 185():114301. PubMed ID: 35439570
[TBL] [Abstract][Full Text] [Related]
36. Determination of CAR T cell metabolism in an optimized protocol.
Joaquina S; Forcados C; Caulier B; Inderberg EM; Wälchli S
Front Bioeng Biotechnol; 2023; 11():1207576. PubMed ID: 37409169
[TBL] [Abstract][Full Text] [Related]
37. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy.
Chen X; Yang S; Li S; Qu Y; Wang HY; Liu J; Dunn ZS; Cinay GE; MacMullan MA; Hu F; Zhang X; Wang P
Mol Ther Oncolytics; 2021 Jun; 21():144-157. PubMed ID: 33981830
[TBL] [Abstract][Full Text] [Related]
38. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
39. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
40. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
